As of February 17, 2026, Danaher Corporation (NYSE: DHR) finds itself at a pivotal juncture in its multi-decade evolution. Once the darling of the "compounding" investment community, the Washington, D.C.-based life sciences giant has recently seen its share price retreat from 2025 highs, currently trading down approximately 11% year-to-date. This volatility follows a complex narrative: [...]
The deal will entail Danaher paying $180 per share for Masimo, reflecting about 18 times Masimo’s projected 2027 earnings before interest, taxes, depreciation, and amortization.
On February 11, 2026, the global water technology leader Xylem Inc (NYSE: XYL) finds itself at a critical crossroads. Following the release of its full-year 2025 earnings report just yesterday, the market has reacted with a complex mixture of admiration and apprehension. While Xylem achieved record-breaking revenue and successfully integrated its massive $7.5 billion Evoqua [...]
As of February 10, 2026, Waters Corporation (NYSE: WAT) stands at the most significant crossroads in its nearly 70-year history. Long regarded as the gold standard in liquid chromatography and mass spectrometry, the Milford, Massachusetts-based company has recently transitioned from a specialized toolmaker into a multi-disciplinary life sciences juggernaut. With the closing of its massive [...]
As of February 5, 2026, Fortive Corp (NYSE: FTV) finds itself at a pivotal crossroads. Long known as the "industrial-tech compounder" born from the Danaher heritage, the company has recently completed a massive structural transformation. Following the 2025 spin-off of its Precision Technologies segment into a standalone entity called Ralliant Corporation, the "New Fortive" has [...]
Date: February 5, 2026 Introduction In the high-stakes world of life sciences, the "cold chain" is the invisible backbone of modern medicine. From the development of mRNA vaccines to the emerging frontiers of cell and gene therapy (CGT), the ability to store, manage, and analyze biological samples with absolute precision is no longer a luxury—it [...]
Danaher’s fourth quarter results met Wall Street’s revenue expectations, with management attributing performance to ongoing strength in its bioprocessing segment and steady growth in diagnostics. CEO Rainer Blair noted that bioprocessing consumables demand, especially for monoclonal antibodies, remained robust, while diagnostic platforms benefited from an active respiratory season and expanding test menus. However, management acknowledged ongoing softness in academic and government research funding, with Blair describing these end markets as “muted but stable.” The company also cited the impact of productivity initiatives and continued investment in new product development as central to offsetting cost pressures.
Diversified science and technology company Danaher (NYSE:DHR) met Wall Streets revenue expectations in Q4 CY2025, with sales up 4.6% year on year to $6.84 billion. Its non-GAAP profit of $2.23 per share was 1.8% above analysts’ consensus estimates.
In the high-stakes world of the S&P 500, few companies have mastered the art of the "quiet compounder" as effectively as Roper Technologies, Inc. (NYSE: ROP). Long known as the textbook example of a successful industrial-to-tech pivot, Roper has built a multi-billion dollar empire by operating in the shadows of niche software markets. However, as [...]
Diversified science and technology company Danaher (NYSE:DHR) met Wall Streets revenue expectations in Q4 CY2025, with sales up 4.6% year on year to $6.84 billion. Its non-GAAP profit of $2.23 per share was 1.8% above analysts’ consensus estimates.
As of January 27, 2026, the financial landscape has undergone a dramatic transformation. After a prolonged "deal winter" that chilled the markets through 2023 and much of 2024, the small-cap sector is currently witnessing an unprecedented resurgence in Mergers and Acquisitions (M&A). This revival is being fueled by a
Abbott Laboratories (NYSE: ABT) saw its stock price tumble by nearly 10% in early trading on January 22, 2026, following the release of its fourth-quarter 2025 financial results. Despite meeting bottom-line expectations for earnings per share, the healthcare giant reported a significant revenue miss that spooked investors, driven primarily by
The S&P 500 (^GSPC) is home to the biggest and most well-known companies in the market, making it a go-to index for investors seeking stability.
But not all large-cap stocks are created equal - some are struggling with slowing growth, declining margins, or increased competition.
Danaher’s 24.7% return over the past six months has outpaced the S&P 500 by 14.7%, and its stock price has climbed to $234.55 per share. This performance may have investors wondering how to approach the situation.
Danaher has had an impressive run over the past six months as its shares have beaten the S&P 500 by 15.6%. The stock now trades at $236.20, marking a 25.6% gain. This performance may have investors wondering how to approach the situation.
Date: January 19, 2026 Author: Finterra Research Team Introduction As the opening bell prepares to ring on a new week, all eyes in the industrial sector are fixed on St. Paul. 3M Company (NYSE: MMM), once the poster child for "litigation-induced value traps," has undergone a metamorphosis over the last 24 months. Today, on the [...]
The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take a look at how research tools & consumables stocks fared in Q3, starting with Danaher (NYSE:DHR).
